Exosome-Based Drug Delivery Service
Inquiry
From nucleic acid therapeutics to protein-based therapies, a wide array of highly promising innovative modalities face a common challenge in clinical translation, efficient and safe in vivo delivery. Exosomes, with low immunogenicity, high biocompatibility, and engineerable targeting capabilities, are emerging as a revolutionary platform in the field of drug delivery. Alfa Cytology's exosome-based drug delivery Service provides end-to-end solutions spanning engineering modification, cargo loading, and functional validation, empowering you to precisely deliver innovative therapeutics to diseased sites, enhance efficacy, and minimize off-target toxicity.
Introduction to Exosome-Based Drug Delivery
Exosomes are naturally secreted, 30–150 nm lipid bilayer vesicles derived from cells. As endogenous mediators of intercellular communication, they offer distinct advantages as an ideal drug delivery system, including exceptionally low immunogenicity, high physicochemical stability, and the ability to protect encapsulated therapeutic agents from degradation, along with inherent targeting capabilities. Compared to synthetic nanocarriers such as liposomes, exosomes demonstrate superior efficiency in the delivery of nucleic acids and proteins. Distinguishing themselves from synthetic vectors, exosomes uniquely combine native cell-homing properties with engineerable targeting potential. Through surface conjugation of targeting ligands (e.g., antibodies, peptides, or aptamers) or genetic engineering of donor cells, exosomes can be precisely directed to tumor tissues, enabling active targeted delivery. This precision-guiding capability significantly enhances local drug concentration, fundamentally reduces off-target toxicity, and broadens the therapeutic window. Currently, exosome-based drug delivery platforms have advanced into clinical development, with multiple programs having received FDA IND clearance for targeted therapy of solid tumors.
Fig. 1 An overview of drug delivery using exosomes. (Vriti S, et al.; 2024)
Our Services
At Alfa Cytology, our exosome services are designed to support every stage of your cancer research and therapeutic development programs. From the initial isolation and characterization of exosomes to advanced multi-omics profiling, biomarker discovery, liquid biopsy development, drug delivery, and personalized therapy applications, we provide end-to-end solutions tailored to your specific research needs.
Exosome Targeted Functionalization
We offer advanced engineering strategies to transform exosomes into precision-guided delivery systems with active targeting capabilities.
- Surface Ligand Conjugation: Covalent attachment of targeting peptides, nanobodies, or small-molecule ligands (e.g., folate) via chemical crosslinking or click chemistry.
- Genetic Engineering: Gene editing of donor cells for native expression of targeting proteins.
- Membrane Insertion: Insertion of hydrophobically modified targeting molecules into the exosome lipid bilayer.
- Dual/Multi-Targeting: Dual or multi-specific recognition to overcome tumor heterogeneity and enhance binding affinity.
Therapeutic Cargo Loading
Utilizing optimized loading strategies tailored to the physicochemical properties of various therapeutic modalities, ensuring high encapsulation efficiency and protection of drug activity.
- Small Molecule Loading: Encapsulation of conventional chemotherapeutics and targeted small-molecule inhibitors.
- Nucleic Acid Loading: Encapsulation of siRNA, mRNA, miRNA, ASOs, DNA plasmids, and other nucleic acid-based therapeutics.
- Protein/Peptide Loading: Encapsulation of therapeutic proteins, antibodies, and peptide-based drugs.
- Combination Loading: Co-loading of multiple therapeutic modalities to support combination therapy strategies.
Exosome Characterization & Quality Control
A multi-dimensional, full-process characterization system to ensure batch-to-batch consistency and functional integrity, covering physical attributes through biological functionality.
- Physical Characterization: NTA (particle size distribution), Zeta potential (stability), TEM (morphology and membrane integrity).
- Marker Identification: Western Blot and flow cytometry detection of canonical exosomal markers including CD9, CD63, CD81, TSG101, and ALIX.
- Targeting Modification Validation: Immunogold labeling, flow cytometry, or ELISA to verify targeting ligand expression efficiency and binding activity.
- Cargo Loading Validation: HPLC, LC-MS, or fluorescence-based methods for quantitative assessment of loading efficiency and cargo integrity.
Functional Validation Support
End-to-end technical support spanning from in vitro activity evaluation and in vivo pharmacodynamic studies to scalable manufacturing.
- In Vitro Functional Validation: Cellular uptake assays, cytotoxicity testing, and mechanism-of-action studies.
- In Vivo Functional Validation: Biodistribution analysis, pharmacodynamic evaluation, and preliminary safety assessment in relevant tumor animal models.
Supported Therapeutic Modalities
Our exosome-based drug delivery platform supports a broad spectrum of anti-tumor therapeutic modalities, covering the complete landscape from traditional small molecules to next-generation biotherapies. The inherent drug-loading capacity, low immunogenicity, and engineerable targeting properties of exosomes position them as ideal delivery vehicles for the following classes of therapeutic agents:
Areas of Expertise in Oncology
Our exosome drug delivery platform is particularly well-suited for oncology applications, with demonstrated expertise across multiple cancer types:
Breast Cancer
Cervical Cancer
Esophageal Cancer
Melanoma
Pancreatic Cancer
Pharyngeal Cancer
Exosome-based drug delivery is redefining the boundaries of precision medicine. Alfa Cytology provides you with customized delivery solutions spanning targeted engineering, cargo loading, and preclinical validation. Leveraging our deep expertise in exosome development and a comprehensive translational medicine platform, we offer full-chain support from feasibility studies to IND-enabling development, accelerating your innovative therapeutics toward the clinic. Please don't hesitate to contact us to discuss your project requirements and receive a customized service proposal.
References
- Vriti S, et al. Exosome as drug delivery system: Current advancements. Extracellular Vesicle. 2024;3:100032.
- Serrano DR, et al. Exosome-Based Drug Delivery: A Next-Generation Platform for Cancer, Infection, Neurological and Immunological Diseases, Gene Therapy and Regenerative Medicine. Pharmaceutics. 2025;17(10):1336.
For research use only.
Related Services
